Related Experiment Video

Updated: Mar 26, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

PARP inhibition in castration-resistant prostate cancer

Lucia Nappi1, Martin E Gleave1

  • 1Vancouver Prostate Centre & Department of Urologic Science, University of British Columbia, Vancouver, British Columbia, Canada.

Future Oncology (London, England)
|January 22, 2016
PubMed
Abstract

No abstract available in PubMed .

Keywords:
DNA repair gene mutationsPARP inhibitorscastration-resistant prostate cancergene sequencingtargeted therapy

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.1K

Related Experiment Videos

Last Updated: Mar 26, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Negative Regulator Molecules01:23

Negative Regulator Molecules

38.9K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K

Articles linked to this work by shared authors, journal, and citation graph.

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.

Cells·2026

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Nature communications·2026

The predictive value of lesion density in enhancing multiparametric MRI for detecting clinically significant prostate cancer.

Urologic oncology·2026

Novel High-Dose Chemotherapy Regimens in Relapsed/Refractory Germ Cell Cancer: Have We Made Progress?

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses.

European urology oncology·2025

Machine Learning Model Integrating Computed Tomography Image-Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer.

JCO clinical cancer informatics·2025

The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?

Future oncology (London, England)·2026

Study protocol on quality of life and erectile function recovery in unfavorable intermediate-risk prostate cancer: REDI-CaP trial.

Future oncology (London, England)·2026

PSMA-PET/mpMRI-guided focal dose-escalated stereotactic body radiotherapy for localized prostate cancer: study protocol for a prospective, randomized controlled trial.

Future oncology (London, England)·2026

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

Future oncology (London, England)·2026

Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences.

Future oncology (London, England)·2026

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.

Future oncology (London, England)·2026

Macrolide-Induced Aldosterone Suppression as a Functional Marker of KCNJ5-Mutated Aldosterone-Producing Adenoma: A Proof-of-Concept Clinical and Experimental Study (MAPA Study).

European journal of endocrinology·2026

Glucagon-like peptide-1 receptor agonist treatment is associated with lower frequency of diabetic peripheral neuropathy and neuropathic pain in type 2 diabetes.

Pain·2026

Predicting GLP-1 Discontinuation From Pharmacy Claims.

The American journal of managed care·2026

Long-term efficacy of adjunctive cenobamate: Open-label extension of a randomized, placebo-controlled study in a multinational Asian population.

Epilepsia·2026

A novel SUR1-TMD0 interaction region contributes to glucose-dependent inhibition of pancreatic KATP channels by bupropion.

British journal of pharmacology·2026

Paliperidone-induced diabetes mellitus presenting with hyperosmolar hyperglycemic state: a case report.

Acta clinica Belgica·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us